NCT05578495 Association of a Digital Signature of Physical Activity and Sedentary Lifestyle With the Development of Multimorbidities in Chronic Diseases (eMOB)
| NCT ID | NCT05578495 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Clermont-Ferrand |
| Condition | Exercise |
| Study Type | INTERVENTIONAL |
| Enrollment | 700 participants |
| Start Date | 2023-12-07 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 700 participants in total. It began in 2023-12-07 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Physical activity (PA) and sedentary lifestyle are determinants in the development of chronic diseases and associated quality of life alterations. PA levels are correlated with quality of life and morbidity in chronic lung disease (COPD), cardiovascular disease, diabetes, cancer, chronic inflammatory rheumatism, fibromyalgia and anxiety disorders. In these diseases, low-intensity PA often represents the main PA and the quantity of PA is correlated with health parameters. This study aims to identify a typical profile (signature) in relation to the appearance of other chronic diseases, complications of your disease, from recording your physical activity and sedentary lifestyle by sensors evaluating very precisely the movements and taking into account the characteristics and disability related to your disease. The results of this study would therefore make it possible to identify this signature even before the appearance of complications or other diseases.
Eligibility Criteria
Inclusion Criteria: * Patient follow-up at CHU Clermont-Ferrand for a chronic disease in one of the following observational cohorts: * Inflammatory rheumatic disease(rheumatoid arthritis, spondyloarthritis) included in the RCVRIC cohort (CPP Sud-Est VI N° ID-RCB- A01847-40) * Pre-surgical knee and hip osteoarthritis (Evalmob) (ID-RCB N° 2019- A01017-50) * Major depressive disorder included in the FACE-DR cohort (CNIL agreement: DR- 2015-673) and Bipolar disorder included in the FACE-BD cohort (CPP Ile de France IX; January 18, 2010) of the Adult Psychiatry Department B * Type 2 diabetes included in the cohort of the sport medicine service "Rehabilitation T2" (CNIL agreement 0164) * Obesity included in the "Obesity" sports medicine service cohort (CNIL agreement 0164) * COPD included in the "COPD Rehabilitation" sports medicine service cohort (CNIL agreement 0164) * Chronic pain cohort (eDOL) (CPP West II N° ID-RCB 2020-A02027-32) * Affiliation to a social security system. * Able to provide written informed consent to participate in the research. Exclusion Criteria: * Inability to practice physical activity * Pregnant or breastfeeding * Refusal to participate * Minors or adults under the protection of the law or under the protection of justice.
Contact & Investigator
Anne Tournadre
PRINCIPAL INVESTIGATOR
University Hospital, Clermont-Ferrand
Frequently Asked Questions
Who can join the NCT05578495 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Exercise. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05578495 currently recruiting?
Yes, NCT05578495 is actively recruiting participants. Contact the research team at promo_interne_drci@chu-clermontferrand.fr for enrollment information.
Where is the NCT05578495 trial being conducted?
This trial is being conducted at Clermont-Ferrand, France.
Who is sponsoring the NCT05578495 clinical trial?
NCT05578495 is sponsored by University Hospital, Clermont-Ferrand. The principal investigator is Anne Tournadre at University Hospital, Clermont-Ferrand. The trial plans to enroll 700 participants.